<DOC>
	<DOCNO>NCT01972568</DOCNO>
	<brief_summary>This multi-center , double-blind , randomize , Phase 2b trial evaluate efficacy atacicept subject systemic lupus erythematosus ( SLE ) .</brief_summary>
	<brief_title>Efficacy Safety Atacicept Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Eligible male female subject , age 18 year old Must least moderately active SLE , define SLE Disease Activity Index2000 ( SLEDAI2K ) score great equal [ &gt; = ] 6 screen visit At least 4 11 American college rheumatology ( ACR ) classification criterion SLE ( diagnose &gt; = 6 month prior screen visit ) Be seropositive antinuclear antibody ( ANA ) and/or antidoublestranded deoxyribonucleic acid ( antidsDNA ) antibodies Other protocol define inclusion criterion could apply Subjects demyelinate disorder Severe central nervous system SLE Use cyclophosphamide within 3 month screen visit Urine protein : creatinine ratio ( UPCr ) &gt; = 2 milligram per milligram ( mg/mg ) per day Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atacicept 75 150 mg</keyword>
	<keyword>Placebo</keyword>
</DOC>